What is the 13F Pro Quality Score for IBO?

13F Pro ranks IMPACT BIOMEDICAL INC. (IBO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IBO's current score at https://13fpro.ai/company/IBO (free sign-up required for the full ranking).

Where does 13F Pro source IBO data?

All IMPACT BIOMEDICAL INC. fundamentals and ownership data come directly from SEC EDGAR. IMPACT BIOMEDICAL INC. files with the SEC under CIK 1834105. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IBO in?

IMPACT BIOMEDICAL INC. (IBO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IBO research updated on 13F Pro?

IBO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IMPACT BIOMEDICAL INC.(IBO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1834105 IBO stock profile & AI dashboard →

13F Pro Quality Score

33.9/100

Rank #2,365 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IBO Scores 34/100

exact factor attribution · 2026-09-11

IBO's composite is driven by profitability and earnings growth, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+7.5 pts

100th pct

Earnings growth

+2.2 pts

95th pct

Capital efficiency

+1.9 pts

69th pct

Earnings quality

-1.1 pts

39th pct

Institutional flow

-1.1 pts

29th pct

Shareholder dilution

-2.1 pts

9th pct

Free cash flow

-6.9 pts

4th pct

Scale

-7.4 pts

0th pct

Revenue growth

-9.2 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

IBO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for IMPACT BIOMEDICAL INC. (IBO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IBO at 33.9/100 on a 32-signal composite quality model, placing it at rank #2,365 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), IMPACT BIOMEDICAL INC. reports quarterly revenue of $3.0K, net income of $-699.0K. Top institutional holders of IBO by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. IBO trades on the NYSE exchange and files with the SEC under CIK 1834105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IBO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMPACT BIOMEDICAL INC. directly from SEC EDGAR. IMPACT BIOMEDICAL INC.'s 13F Pro composite quality score has ranged between 20 and 34 since 2026, currently 33.9 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q2 2026

$3.0K

Net Income

Q2 2026

$-699.0K

ROIC

Q2 2026

-26.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$32.0KFY 2025

FY22 $50.0KFY23 —FY24 —FY25 $32.0K

Net Income

+52.1% YoY

$-11.8MFY 2025

FY22 $-7.3MFY23 $-4.3MFY24 $-24.7MFY25 $-11.8M

Operating Income

+85.1% YoY

$-4.3MFY 2025

FY22 $-3.4MFY23 $-4.0MFY24 $-28.8MFY25 $-4.3M

EPS (Diluted)

+83.5% YoY

$-0.38FY 2025

FY22 $-0.00FY23 $-0.07FY24 $-2.30FY25 $-0.38

Total Assets

-14.2% YoY

$17.4MFY 2025

FY22 $46.5MFY23 $44.6MFY24 $20.3MFY25 $17.4M

Op. Cash Flow

+33.8% YoY

$-1.9MFY 2025

FY22 $-2.2MFY23 $-2.9MFY24 $-2.9MFY25 $-1.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$32.0K	—	—	$50.0K	—
Net Income	$-11.8M +52.1%	$-24.7M -469.8%	$-4.3M +40.2%	$-7.3M	—
Operating Income	$-4.3M +85.1%	$-28.8M -613.8%	$-4.0M -18.3%	$-3.4M	—
EPS (Diluted)	$-0.38 +83.5%	$-2.30 -3185.7%	$-0.07 -2087.5%	$-0.00	—
Total Assets	$17.4M -14.2%	$20.3M -54.5%	$44.6M -4.0%	$46.5M	—
Operating Cash Flow	$-1.9M +33.8%	$-2.9M -0.1%	$-2.9M -27.2%	$-2.2M	—

Get alerted when IBO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IMPACT BIOMEDICAL INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IBO

GEODE CAPITAL MANAGEMENT, LLC
$545.6K1,185,163 sh
VANGUARD CAPITAL MANAGEMENT LLC
$372.0K808,689 sh
STATE STREET CORP
$279.6K607,897 sh
VANGUARD FIDUCIARY TRUST CO
$271.1K589,428 sh
BlackRock, Inc.
$119.6K259,946 sh
NORTHERN TRUST CORP
$108.3K235,475 sh
CITADEL ADVISORS LLC
$22.8K49,567 sh
Vanguard Global Advisers, LLC
$14.8K32,201 sh
JANE STREET GROUP, LLC
$11.3K24,528 sh
TWO SIGMA INVESTMENTS, LP
$7.9K17,191 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$545.6K	1,185,163
VANGUARD CAPITAL MANAGEMENT LLC	$372.0K	808,689
STATE STREET CORP	$279.6K	607,897
VANGUARD FIDUCIARY TRUST CO	$271.1K	589,428
BlackRock, Inc.	$119.6K	259,946
NORTHERN TRUST CORP	$108.3K	235,475
CITADEL ADVISORS LLC	$22.8K	49,567
Vanguard Global Advisers, LLC	$14.8K	32,201
JANE STREET GROUP, LLC	$11.3K	24,528
TWO SIGMA INVESTMENTS, LP	$7.9K	17,191

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IBO on your watchlist

Track score changes the day IMPACT BIOMEDICAL INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IBO a good stock to buy?

13F Pro's AI-powered analysis of IMPACT BIOMEDICAL INC. (IBO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IBO are available on the IBO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IBO is classified as a small company.

Which hedge funds own IBO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IBO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IMPACT BIOMEDICAL INC.'s investment landscape.